Evotec to discover and develop first-in-class oncology therapeutics in research tie-up

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/CIPhotos)
(Image: Getty/CIPhotos)

Related tags: Evotec, Oncology, Drug discovery, Drug development

Evotec AG is partnering with the Mark Foundation for Cancer Research to discover and develop first-in-class therapeutics in oncology using its new drug discovery platform.

The research collaboration will leverage Evotec’s new proprietary drug discovery platform TargetAlloMod and is initially set to last two years.

The platform has applicability across therapeutic areas, including a suite of assay principles and computational tools “to assess and screen extracellular receptor targets for shedding and the induction of shedding by small molecule allosteric modulators,”​ according to the company.

Under terms of the agreement, the Mark Foundation for Cancer Research will provide research funding to Evotec, which will be in charge of partnerships.

The NY-based foundation will expand it is grant portfolio – focused on oncology research and drug discovery – with any potential financial returns.

Financial terms were not disclosed.

Evotec earlier this month announced ​a partnership with a global non-profit research group to develop a pipeline of novel antibiotics after integrating Sanofi’s infectious disease unit last year.

The strategic public-private partnership with the Global Antibiotic Research and Development Partnership (GARDP) will address the threat posed by antimicrobial resistance (AMR).

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related products

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Products

View more

Webinars